Tanaka H, et al. - The researchers assessed the long-term retention rate and prognostic factors associated with the discontinuation of adalimumab treatment in patients with Crohn's disease in this large, multicenter, retrospective cohort study. A good retention rate of adalimumab was observed in patients with Crohn's disease over a 4-year period. Factors associated with poor retention of adalimumab treatment were female sex, perianal disease, concomitant treatment with prednisolone at baseline, previous infliximab use, higher C-reactive protein levels, and lower albumin levels.